Fig 1.
Study flowchart for patient selection.
HTM, HIV-associated Talaromyces marneffei; HTMF, HIV-associated Talaromyces marneffei fungemia; (+), positive; NGS, next-generation sequencing; BALF, bronchoalveolar lavage fluid; iAmBd + iVori, a combination of iAmBd and iVori; iAmBd, initial induction treatment with amphotericin B deoxycholate; iVori, initial induction treatment with voriconazole; iVori→AmBd switch, switch regimen from initial treatment with voriconazole to AmBd during induction stage.
Table 1.
The baseline participant demographics, clinical, and laboratory features.
Fig 2.
The 180-day cumulative survival rate in HTM patients with and without fungemia.
HTMF, HIV-associated Talaromyces marneffei patient with fungemia; Non-HTMF, HIV-associated Talaromyces marneffei patient without fungemia.
Fig 3.
The 180-day cumulative survival rate in HTMF patients with different initial induction treatment.
iAmBd, initial induction treatment with amphotericin B deoxycholate; iVori, initial induction treatment with voriconazle.
Fig 4.
The 180-day cumulative survival rate in patients with different switch regimens.
iAmBd, initial induction treatment with amphotericin B deoxycholate; iVori, initial induction treatment with voriconazle; iVori→AmBd switch, switch regimen from initial treatment with voriconazole to AmBd during induction stage.
Fig 5.
180-day all-cause mortality and initial AmBd treatment.
AmBd: patients treated with iAmBd and switched AmBd; iVori: patients continued iVori without iVori→AmBd switch.